Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future …

PY Wen, M Weller, EQ Lee, BM Alexander… - Neuro …, 2020 - academic.oup.com
Glioblastomas are the most common form of malignant primary brain tumor and an important
cause of morbidity and mortality. In recent years there have been important advances in …

Primary brain tumours in adults

MJ van den Bent, M Geurts, PJ French, M Smits… - The Lancet, 2023 - thelancet.com
The most frequent adult-type primary CNS tumours are diffuse gliomas, but a large variety of
rarer CNS tumour types exists. The classification of these tumours is increasingly based on …

Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways

S Venneti, AR Kawakibi, S Ji, SM Waszak, SR Sweha… - Cancer discovery, 2023 - AACR
Abstract Patients with H3K27M-mutant diffuse midline glioma (DMG) have no proven
effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the …

Targeting apoptotic pathways for cancer therapy

X Tian, PR Srinivasan, V Tajiknia… - The Journal of clinical …, 2024 - jci.org
Apoptosis is a form of programmed cell death that is mediated by intrinsic and extrinsic
pathways. Dysregulation of and resistance to cell death are hallmarks of cancer. For over …

[HTML][HTML] ONC201 and imipridones: Anti-cancer compounds with clinical efficacy

VV Prabhu, S Morrow, AR Kawakibi, L Zhou, M Ralff… - Neoplasia, 2020 - Elsevier
ONC201 was originally discovered as TNF-Related Apoptosis Inducing Ligand (TRAIL)-
inducing compound TIC10. ONC201 appears to act as a selective antagonist of the G …

A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials

E Cruz Da Silva, MC Mercier, N Etienne-Selloum… - Cancers, 2021 - mdpi.com
Simple Summary This review describes in a very detailed and exhaustive approach the
literature of these last 20 years on glioblastoma targeted therapies in Phases II-IV of 257 …

Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas

JM Przystal, C Cianciolo Cosentino, S Yadavilli… - Neuro …, 2022 - academic.oup.com
Background Pediatric diffuse midline gliomas (DMGs) are incurable childhood cancers. The
imipridone ONC201 has shown early clinical efficacy in a subset of DMGs. However, the …

Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma

E Cantor, K Wierzbicki, RS Tarapore, K Ravi… - Neuro …, 2022 - academic.oup.com
Abstract Background Diffuse Midline Glioma (DMG) with the H3K27M mutation is a lethal
childhood brain cancer, with patients rarely surviving 2 years from diagnosis. Methods We …

Mitochondrial quality control proteases and their modulation for cancer therapy

J Zhang, W Qiao, Y Luo - Medicinal Research Reviews, 2023 - Wiley Online Library
Mitochondria, the main provider of energy in eukaryotic cells, contains more than 1000
different proteins and is closely related to the development of cells. However, damaged …

[HTML][HTML] A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3 Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults

C Ekhator, R Rak, R Tadipatri, E Fonkem, J Grewal - Cureus, 2022 - ncbi.nlm.nih.gov
A Single-Center Experience of Dopamine Antagonist ONC201 for Recurrent Histone H3
Lysine 27-to-Methionine (H3K27M)-Mutant Glioblastoma in Adults - PMC Back to Top Skip to …